UCL Queen Square Institute of Neurology


Research Excellence and Impact

Research at the Institute focuses on basic and clinical research related to neurological disorders research. The mission is to translate neuroscience discovery research into treatments for patients with neurological diseases. Interactions within the UCL Research, the UCL Neuroscience and National Hospital are extensive and fruitful.

Please also see the following pages for further information on specific areas of research:

Research excellence
Continuing the record of exceptional achievement in previous Research Assessments (RAE), the Institute performed very strongly in REF2014 within Unit of Assessment (UoA) 4, Psychology, Psychiatry and Neuroscience. UCL came top overall in both the standard power measure and combined 4* and 3* work in this UoA.

Overall, 83 per cent of the submission was rated ‘world-leading’ or ‘internationally excellent’ (4*/3*), with 74% of research outputs given these ratings. The research environment was given a 100% world-leading rating and the impact was judged to be over 97% world leading or internationally excellent. The Institute submitted 163 staff , of whom 17 were early career researchers.   Over 92% of eligible staff were submitted to this UoA.

Please see our REF2014 news item for further details.

This continues our record of exceptional achievement in previous Research Assessment Exercises.

Impact case studies (from the UCL Impact website)

See also case studies on the UCL Dementia research website:

UCL ranked as a leader in academic-corporate and academic collaborations in Alzheimer's research

Elsevier has published a new metric for Alzheimer’s research, which finds that UCL is #3 in the world for Alzheimer’s research (2013-2018), while also being a leader in academic-corporate and academic collaborations. Elsevier’s report entitled Alzheimer’s Disease Research Insights: Impact, Trends, Opportunities finds:

  • UCL is amongst the top three global institutions for scholarly output on Alzheimer’s research between 2013-2018, with Harvard University and the Institut National de la Santé et de la Recherche Médicale narrowly above. This makes UCL the leading institution for Alzheimer’s research output in the UK.
  • Globally, Elsevier’s report finds that UCL is the top university for academic-corporate collaborations in Alzheimer’s research, with 15.2% of UCL research involving a corporate.
  • UCL is the second most prolific institution for international academic collaborations (75.7% of UCL’s output of research in Alzheimer’s disease between 2013-2018).
  • Read the full report

Highly Cited Researchers 2018

UCL has the second highest number of Highly Cited Researchers (HCRs) listed in Neuroscience and Behaviour in the UK (after Oxford): all of whom are from UCL Queen Square Institute of Neurology
IoN has more HCRs in Neuroscience and Behaviour than Imperial, King’s College London and University of Cambridge combined

RAND report shows that UCL has the highest share of highly cited publications in Neurology in England
An independent report by RAND (2015) which examined highly-cited research, i.e. research publications falling into the top 20% for citations in their year and field, showed that UCL has the highest share of Highly Cited Publications (HCPs) in Neuroimaging (21.1%), Neurosciences (18.1%) and Clinical neurology (15.6%) and in the Dementias Highlight Area (15.5%) – in all cases significantly more than the nearest competitor.

Neuroimaging is one of only two subject areas covered in the analysis where one HEI has over 20% of all HCPs

UCL Neuroscience is currently rated second in the world by ISI Essential Science Indicators, and several of the most highly cited authors working worldwide in neuroscience and behaviour are based at the IoN.  

See also our Publications page. 

Funding and support

The Institute currently holds over 602 active grants, for research from the principal medical charities concerned with neurological diseases, and from government agencies such as the Medical Research Council.